Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Ron Harvey who wrote (3019)	6/12/1998 1:27:00 PM
From: TokyoMex	Read Replies (1) \| Respond to of 5736

Chromatics Color Sciences Responds to Asensio's Lies Against Pain-free Tests for Babies NEW YORK, June 12 /PRNewswire/ -- Chromatics Color Sciences International, Inc. (Nasdaq: CCSI), said today that Manual Asensio's assertion that the FDA-approved, non-invasive Colormate(TM) TLc-BiliTest(TM) for pain-free bilirubin testing of newborn babies comes with a disposable feature that costs $20 to $30 a test is total falsehood. Chromatics has never stated this pricing structure for the TLc-Lensette(TM), a disposable calibration standard used with the TLc-BiliTest(TM) for individual calibration and to prevent cross contamination between infants. Conversely, the Company has publicly stated that hospitals charge between $22 and $34 for the currently existing invasive laboratory bilirubin test for newborns that is performed millions of times each year. The cost of the non-invasive TLc-BiliTest(TM) test for newborns, which eliminates pain, scarring and multiple blood drawing for newborn babies would be cost-effective and less labor intensive than the current invasive system, and hospitals should be able to charge the same price per test as they currently do. "Mr. Asensio's false statement is simply another step in his orchestrated attempt to drive down the price of Chromatics' stock for his own self-serving purposes, as, has been reported, he currently holds a 300,000 share short position in CCSI," said Darby S. Macfarlane, chairperson and chief executive officer of Chromatics. "Contrary to the continuous cascade of false statements issued by Mr. Asensio, the Colormate(TM) TLc-BiliTest(TM) is clearly a technological advance that can benefit newborns, their parents, hospitals, attending physicians and nurses. CCSI has been working diligently to see this benefit occur, while Mr. Asensio's outrageous falsehoods are designed to prevent that." Chromatics Color Sciences is in the business of color science and has developed technologies and intellectual properties which it believes have medical applications involving the detection and monitoring of certain chromogenic diseases or disorders such as bilirubin infant jaundice. The Company defines chromogenic diseases or disorders as those diagnosed or monitored by the coloration of the human skin, tissue or fluid being affected. In this regard, the Company has received Food and Drug Administration (FDA) clearance for commercial marketing of its medical device for detection and monitoring of bilirubin infant jaundice. Other medical applications will require additional clinical trials and FDA clearance. The Company's technologies and intellectual properties also have other applications, including the scientific color measurement and classification of human skin, certain color-sensitive consumer products, and in determining the color compatibility of such skin and product color classification for use in a variety of industries including the cosmetic, beauty-aid and fashion industries. Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business which may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, the availability of any needed financing, the Company's ability to implement its long range business plan for various applications for its technologies, the impact of competition, the obtaining of further regulatory clearances applicable to proposed new applications of the Company's technology, management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, including those set forth in its annual report on Form 10-K for the year ended December 31, 1997. SOURCE Chromatics Color Sciences International, Inc. CO: Chromatics Color Sciences International, Inc. ST: New York IN: MTC SU: 06/12/98 13:21 EDT prnewswire.com To edit your profile, go to keyword NewsProfiles. For all of today's news, go to keyword News.

To: Ron Harvey who wrote (3019)	6/12/1998 1:32:00 PM
From: TokyoMex	Read Replies (1) \| Respond to of 5736

Matter of signing I heard... ROFLMAO ,, Asensio has lousy 300,000 shares ,, gggg thought he was a big money bag..

To: Ron Harvey who wrote (3019)	6/12/1998 3:37:00 PM
From: Spunky Beaver	Respond to of 5736

<<The only thing that will turn this stock around now that Asensio has found it is REVENUES or the timely announcement of a significant DEAL.>> I would like to add that something else that could turn this thing around is some good old fashioned Insider buying or a CCSI stock buy back. But judging from past Insider selling, and I pointed out insider selling on this thread a half year ago when I was long on this stock (see exchange2000.com, I am skeptical of any of the above happening.